logo
Share SHARE
FONT-SIZE Plus   Neg

Abbott Xience Xpedition Drug Eluting Stent Gets Approval In Japan

Healthcare company Abbott Laboratories (ABT) said Wednesday that it has received approval for its next-generation Xience Xpedition everolimus eluting coronary stent system in Japan. The approval boosts Abbott's efforts to globally expand its drug-eluting stent systems.

The company said that Japan's Ministry of Health, Labor and Welfare approved the Xience Xpedition stent for the treatment of coronary artery disease or CAD, the most common form of heart disease, in Japan. Heart disease is one of the leading causes of death in Japan, accounting for nearly one-third of all deaths in the country.

Abbott noted that the Xience Xpedition's enhanced deliverability, combined with the broadest size matrix in the Japanese market that includes a unique 3.25 mm diameter for more accurate vessel sizing, will help physicians in Japan address a wide range of patients with CAD.

Masahisa Yamane, director, Cardiovascular Division of Saitama Sekishinkai Hospital in Saitama, Japan said, "The deliverability with Xience Xpedition is impressive, helping physicians navigate with ease through complex blockages inside the heart vessels. This approval offers physicians an important new treatment option to address a growing health concern in Japan; we look forward to the positive impact of this product in Japanese patients with coronary heart disease."

Xience Xpedition is currently available in the U.S, Europe, the Middle East and parts of Asia.

In Japan, five Abbott-sponsored trials involving more than 3,000 patients implanted with either Xience V or Xience Prime have been conducted. Several other studies, including investigator-initiated trials, have been conducted since the original launch in Japan of Xience V in 2010.

In Wednesday's regular trading session, ABT is trading at $35.07, up $0.33 or 0.94 percent on a volume of 906,625 shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Activision Blizzard Inc. (ATVI) on Thursday reported a drop in profit for the fourth quarter, as revenues declined reflecting weak demand for Skylanders SuperChargers and Guitar Hero Live. The video game publisher's profit and revenues fell short of Wall Street estimates. Moving ahead, the company detailed... CBS Corp. (CBS, CBS-A) Thursday reported a drop in profit for the fourth quarter, hurt largely by one-time charges. However, on an adjusted basis, earnings for the three-month period increased on higher revenues across all major segments, except local broadcasting division. The New York-based company's... Tesla's next electric car Model 3 is aimed at the masses with a price tag that could go below $30,000. Tesla CEO Elon Musk, during an earnings call, confirmed that the Model 3 will start selling for "around $35k," and reservations will start from March 31 in Tesla stores and online on April 1 for...
comments powered by Disqus
RELATED NEWS
Trade ABT now with 
Follow RTT